[Therapeutic management of cognitive disorders in multiple sclerosis]

Abstract : Taking in charge cognitive disorders is a new concept in the global care of MS patients. Cognitive disorders are observed in the all forms of the disease, sometimes early on in the evolution. These disorders can be evaluated in details even detected despite any complain in the patient. Because of the lack of clear demonstration that disease-modifying treatments could act on cognition, new specific therapeutic issues have emerged during last years. This article first discusses relationships between disease-modifying treatments and cognition for the different forms of the disease, then analyse the effects of symptomatic drug therapy especially the use of anticholinesterasics. In the last part of the article new issues about antagonists of excitatory amino-acids and individual or group cognitive training are discussed. Recent functional imaging data concerning cerebral adaptation and their modifications by drug or non-drug procedures in MS patients suggest interesting therapeutic development in a next future.
Type de document :
Article dans une revue
Revue Neurologique, Elsevier Masson, 2007, 163 (6-7), pp.703-10
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00383224
Contributeur : Francis Eustache <>
Soumis le : mardi 12 mai 2009 - 14:39:36
Dernière modification le : mardi 24 avril 2018 - 01:39:49
Document(s) archivé(s) le : jeudi 10 juin 2010 - 21:18:35

Fichiers

Defer_et_al_Prise_en_charge_th...
Fichiers produits par l'(les) auteur(s)

Identifiants

  • HAL Id : inserm-00383224, version 1
  • PUBMED : 17607193

Citation

Gilles-Louis Defer, France Daniel, Nathalie Derache. [Therapeutic management of cognitive disorders in multiple sclerosis]. Revue Neurologique, Elsevier Masson, 2007, 163 (6-7), pp.703-10. 〈inserm-00383224〉

Partager

Métriques

Consultations de la notice

335

Téléchargements de fichiers

1741